Inhaled albuterol/salbutamol and ipratropium bromide and their combination in the treatment of chronic obstructive pulmonary disease

Bibliography

• Available from: www.goldcopd.com. [Accessed 3 September 2009]
   Google Scholar
• Barnes PJ, Celli BR. Systemic manifestation and comorbidities of COPD. Eur Respir J 2009;33:1165-85
   PubMed Web of Science ®Google Scholar
• Decramer M, Rennard S, Troosters T, COPD as a lung disease with systemic consequences-clinical impact, mechanisms, and potential for early intervention. COPD 2008;5:235-56
   PubMedGoogle Scholar
• Agusti A, Soriano JB. COPD as a systemic disease. COPD 2008;5:133-8
   PubMedGoogle Scholar
• Fabbri LM, Luppi F, Beghe B, Rabe KF. Complex chronic comorbidities of COPD. Eur Respir J 2008;31:204-12
   PubMed Web of Science ®Google Scholar
• Van Eeden SF, Sin DD. Chronic obstructive pulmonary disease: a chronic systemic inflammatory disease. Respiration 2008;75:224-38
   PubMed Web of Science ®Google Scholar
• Vollmer WM, Gislason T, Burney P, Comparison of spirometry criteria for the diagnosis of COPD: results from the BOLD study. Eur Respir J 2009;34:588-97
   PubMed Web of Science ®Google Scholar
• FDA website. 2010. Available from: http://www.accessdata.fda.gov/Scripts/cder/DrugsatFDA/index.cfm?fuseaction=Search.DrugDetails
   Google Scholar
• Brunton L, Lazo J, Parker K. The pharmacological basis therapeutics. 11th edition. Goodman & Gilman's, McGraw–Hill Publishers; 2005
   Google Scholar
• RxList: The Internet Drug Index. 2009. Available from: http://www.rxlist.com/albuterol-sulfate-drug.htm
   Google Scholar
• www.medscape.com 2009. Available from: http://www.medscape.com/druginfo/ monograph?cid=med&drugid=5476& drugname=Albuterol+Inhl&monotype=monograph&secid=8
   Google Scholar
• Sears MR, Lötvall J. Past, present and future–beta2-adrenoceptor agonists in asthma management. Respir Med 2005;99(2):152-70
   PubMed Web of Science ®Google Scholar
• Labirism NR, Dolovich MB. Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 2003;56(6):600-12
   PubMed Web of Science ®Google Scholar
• Handoko A, Ian L, Peter SJ. Influence of the polydispersity of the added fine lactose on the dispersion of salmeterol xinafoate from mixtures for inhalation. Eur J Pharm Sci 2009;36(2-3):265-74
   PubMed Web of Science ®Google Scholar
• Newman S, Malik S, Hirst R, Lung deposition of salbutamol in healthy human subjects from the MAGhaler dry powder inhaler. Respir Med 2002;96(12):1026-32
   PubMed Web of Science ®Google Scholar
• Iida K, Hayakawa Y, Okamoto H, Evaluation of flow properties of dry powder inhalation of salbutamol sulfate with lactose carrier. Chem Pharm Bull (Tokyo) 2001;49(10):1326-30
   PubMed Web of Science ®Google Scholar
• McCalden TA, Radhakrishnan R. A comparative study of the bronchodilator effect and duration of action of liposome encapsulated beta-2 adrenergic agonists in the guinea-pig. Pulm Pharmacol 1991;4(3):140-5
   PubMedGoogle Scholar
• Dellamary LA, Tarara TE, Smith DJ, Hollow porous particles in metered dose inhalers. Pharm Res 2000;17(2):168-74
   PubMed Web of Science ®Google Scholar
• RxList: The Internet Drug Index. 2009. Available from: http://www.rxlist.com/atrovent-hfa-drug.htm
   Google Scholar
• RxList: The Internet Drug Index. 2009. Available from: http://www.rxlist.com/combivent-drug.htm
   Google Scholar
• RxList: The Internet Drug Index. 2009. Available from: http://www.rxlist.com/duoneb-drug.htm
   Google Scholar
• Katzung BG. Basic and clinical pharmacology. 6th edition. Appleton-Century-Crofts and Fleschner; 1994
   Google Scholar
• Wang XS, Lau HY. Beta-adrenoceptor-mediated inhibition of mediator release from human peripheral blood-derived mast cells. Clin Exp Pharmacol Physiol 2006;33(8):746-50
   PubMed Web of Science ®Google Scholar
• Peachell P. Regulation of mast cells by beta-agonists. Clin Rev Allergy Immunol 2006;31(2-3):131-42
   PubMed Web of Science ®Google Scholar
• Wessler I, Kirkpatrick CJ, Racké K. Non-neuronal acetylcholine, a locally acting molecule, widely distributed in biological systems: expression and function in humans. Pharmacol Ther 1998;77(1):59-79
   PubMed Web of Science ®Google Scholar
• Wessler I, Kilbinger H, Bittinger F, Kirkpatrick CJ. The biological role of non-neuronal acetylcholine in plants and humans. Jpn J Pharmacol 2001;85(1):2-10
   PubMedGoogle Scholar
• Repsher LH, Anderson JA, Bush RK, Assessment of tachyphylaxis following prolonged therapy of asthma with inhaled albuterol aerosol. Chest 1984;85(1):34-8
   PubMed Web of Science ®Google Scholar
• Ingram RH, Wellman JJ, McFadden ER, Mead J. Relative contributions of large and small airways to flow limitation in normal subjects before and after atropine and isoproterenol. J Clin Invest 1977;59:696-703
   PubMed Web of Science ®Google Scholar
• Haddad EB, Mak JC, Belvisi MG, Muscarinic and beta-adrenergic receptor expression in peripheral lung from normal and asthmatic patients. Am J Physiol 1996;270(6 Pt 1):L947-53
   PubMedGoogle Scholar
• Hensley MJ, O'Cain CF, McFadden EF, Ingram RH. Distribution of bronchodilatation in normal subjects: beta agonist versus atropine. J Appl Physiol 1978;45:778-82
   PubMed Web of Science ®Google Scholar
• Douglas NJ, Sudlow MF, Flenley DC. Effect of an inhaled atropine-like agent on normal airway function. J Appl Physiol 1979;46(2):256-62
   PubMed Web of Science ®Google Scholar
• Popius H, Salorinne Y. Comparative trial of a new anticholinergic bronchodilator, Sch 1000, and salbutamol in chronic bronchitis. Br Med J 1973;4:134-6
   PubMed Web of Science ®Google Scholar
• Hughes JA, Tobin MJ, Bellamy D, Hutchison DCS. Effects of ipratropium bromide and fenoterol aerosols in pulmonary emphysema. Thorax 1982;37:667-70
   PubMed Web of Science ®Google Scholar
• Gross JNJ, Skorodin MS. Role of the parasympathetic system in airway obstruction due to emphysema. N Engl J Med 1984;311:421-5
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Ashutosh K, Bleecker ER, Comparison of the anticholinergic bronchodilator ipratropium bromide with metaproterenol in chronic obstructive pulmonary disease. A 90-day multi-center study. Am J Med 1986;81(5A):81-90
   PubMed Web of Science ®Google Scholar
• Proskocil BJ, Fyer AD. beta2-Agonist and anticholinergic drugs in the treatment of lung disease. Proc Am Thorac Soc 2005;2:305-10
   PubMedGoogle Scholar
• Bartel S, Karczewski P, Krause EG. Protein phosphorylation and cardiac function: cholinergic-adrenergic interaction. Cardiovasc Res 1993;27:1948-53
   PubMed Web of Science ®Google Scholar
• Pepe S, Xiao RP, Hohl C, Cross talk between opiod peptide and adrenergic receptor signoaling in isolated rat heart. Circulation 1997;95:2122-9
   PubMed Web of Science ®Google Scholar
• Rousell J, Haddad EB, Mak JC, Beta adrenoceptor-medicated down-regulation of M2 muscarinic receptors: role of cyclic adenosine 5′-monophosphate-dependent protein kinase and protein kinase C. Mol Pharmacol 1996;49:629-35
   PubMed Web of Science ®Google Scholar
• Sestini P, Renzoni E, Robinson S, Short-acting beta 2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002;(4):CD001495
   PubMedGoogle Scholar
• Ram FS, Sestini P. Regular inhaled short acting beta2 agonists for the management of stable chronic obstructive pulmonary disease: cochrane systematic review and meta-analysis. Thorax 2003;58(7):580-4
   PubMed Web of Science ®Google Scholar
• Ram FS, Brocklebank DM, Muers M, Pressurised metered-dose inhalers versus all other hand-held inhalers devices to deliver bronchodilators for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002;(1):CD002170
   PubMedGoogle Scholar
• Poole PJ, Saini R, Brodie SM, Black PN. Comparison of the effects of nebulised and inhaled salbutamol on breathlessness in severe COPD. Respir Med 2005;99(3):372-6
   PubMed Web of Science ®Google Scholar
• Ikeda A, Nishimura K, Koyama H, Respiration 1999;66(2):119-22
   PubMed Web of Science ®Google Scholar
• ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary position of the ATS/ERS position paper. Eur Respir J 2004;23:932-46
   PubMed Web of Science ®Google Scholar
• McCrory DC, Brown CD. Anti-cholinergic bronchodilators versus beta2-sympathomimetic agents for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002;(4):CD003900
   PubMedGoogle Scholar
• Mandelberg A, Chen E, Noviski N, Priel IE. Nebulized wet aerosol treatment in emergency department--is it essential? Comparison with large spacer device for metered-dose inhaler. Chest 1997;112(6):1501-5
   PubMed Web of Science ®Google Scholar
• Nair S, Thomas E, Pearson SB, Henry MT. A randomized controlled trial to assess the optimal dose and effect of nebulized albuterol in acute exacerbations of COPD. Chest 2005;128(1):48-54
   PubMed Web of Science ®Google Scholar
• Truitt T, Witko J, Halpern M. Levalbuterol compared to racemic albuterol: efficacy and outcomes in patients hospitalized with COPD or asthma. Chest 2003;123(1):128-35
   PubMed Web of Science ®Google Scholar
• Donohue JF, Hanania NA, Ciubotaru RL, Comparison of levalbuterol and racemic albuterol in hospitalized patients with acute asthma or COPD: a 2-week, multicenter, randomized, open-label study. Clin Ther 2008;30:989-1002
   PubMed Web of Science ®Google Scholar
• Mouloudi E, Katsanoulas K, Anastasaki M, Bronchodilator delivery by metered-dose inhaler in mechanically ventilated COPD patients: influence of tidal volume. Intensive Care Med 1999;25(11):1215-21
   PubMed Web of Science ®Google Scholar
• Malliotakis P, Mouloudi E, Prinianakis G, Influence of respiratory efforts on beta2-agonist induced bronchodilation in mechanically ventilated COPD patients: a prospective clinical study. Respir Med 2007;101(2):300-7
   PubMed Web of Science ®Google Scholar
• Mouloudi E, Prinianakis G, Kondili E, Georgopoulos D. Bronchodilator delivery by metered-dose inhaler in mechanically ventilated COPD patients: influence of flow pattern. Eur Respir J 2000;16(2):263-8
   PubMed Web of Science ®Google Scholar
• Mouloudi E, Maliotakis C, Kondili E, Duration of salbutamol-induced bronchodilation delivered by metered-dose inhaler in mechanically ventilated COPD patients. Monaldi Arch Chest Dis 2001;56(3):189-94
   PubMedGoogle Scholar
• Restrepo RD. Use of inhaled anticholinergic agents in obstructive airway disease. Respir Care 2007;52(7):833-51
   PubMed Web of Science ®Google Scholar
• Campbell S. For COPD a combination of ipratropium bromide and albuterol sulfate is more effective than albuterol base. Arch Intern Med 1999;159:156-60
   PubMed Web of Science ®Google Scholar
• O'Donnell DE, Lam M, Webb KA. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;158(5 Pt 1):1557-65
   PubMed Web of Science ®Google Scholar
• Martin R, Bartelson B, Smith P, Effect of ipratropium bromide treatment on oxygen saturation and sleep quality in COPD. Chest 1999;115:1338-45
   PubMed Web of Science ®Google Scholar
• Witek TJ. Anticholinergic bronchodilators. Respir Care Clin N Am 1999;5:521-36
   PubMedGoogle Scholar
• Anthonisen N, Connett J, Kiley J, Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the lung health study. JAMA 1994;272:1497-505
   PubMed Web of Science ®Google Scholar
• McCrory DC, Brown CD. Anticholinergic bronchodilators versus beta2-sympathomimetic agents for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2003;1:CD003900
   Google Scholar
• Moayyedi P, Congleton J, Page RL, Comparison of nebulized salbutamol and ipratropium bromide with salbutamol alone in the treatment of chronic obstructive pulmonary disease. Thorax 1995;50:834-7
   PubMed Web of Science ®Google Scholar
• Patrick DM, Dales RE, Stark RM, Severe exacerbations of COPD and asthma: incremental benefit of adding ipratropium to usual therapy. Chest 1990;98:295-7
   PubMed Web of Science ®Google Scholar
• Backman R, Hellstrom PE. Fenoterol and ipratropium in respiratory treatment of patients with chronic bronchitis. Curr Ther Res Clin Exp 1985;38:135-40
   Web of Science ®Google Scholar
• Karpel JP, Pesin J, Greenberg D, A comparison of the effects of ipratropium bromide and metaproterenol sulfate in acute exacerbations of COPD. Chest 1990;98:835-9
   PubMed Web of Science ®Google Scholar
• Gross N, Tashkin D, Miller R, Inhalation by nebulization of albuterol-ipratropium combination (Dey combination) is superior to either agent alone in the treatment of chronic obstructive pulmonary disease. Respiration 1998;65(5):354-62
   PubMed Web of Science ®Google Scholar
• COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. Chest 1994;105(5):1411-9
   PubMed Web of Science ®Google Scholar
• Ikeda A, Nishimura K, Koyama H, Izumi T. Bronchodilating effects of combined therapy with clinical dosages of ipratropium bromide and salbutamol for stable COPD: comparison with ipratropium bromide alone. Chest 1995;107(2):401-5
   PubMed Web of Science ®Google Scholar
• The COMBIVENT Inhalation Solution Study Group. Routine nebulized ipratropium and albuterol together are better than either alone in COPD. Chest 1997;112:1514-21
   PubMed Web of Science ®Google Scholar
• Levin DC, Little KS, Laughlin KR, Addition of anticholinergic solution prolongs bronchodilator effect of beta 2 agonists in patients with chronic obstructive pulmonary disease. Am J Med 1996;100(1A):40S-8S
   PubMedGoogle Scholar
• Sansores R, Ramirez-Vanegas A, Reddy C, Mejia-Alfaro R. Effect of the combination of two bronchodilators on breathlessness in patients with chronic obstructive pulmonary disease: a crossover clinical trial. Arch Med Res 2003;34:292-7
   PubMed Web of Science ®Google Scholar
• Friedman M, Serby CW, Menjoge SS, Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest 1999;115(3):635-41
   PubMed Web of Science ®Google Scholar
• Appleton S, Jones T, Poole P, Ipratropium bromide versus short acting beta-2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006;(2):CD001387
   PubMed Web of Science ®Google Scholar
• Abramson MJ, Walters J, Walters EH. Adverse effects of beta-agonists: are they clinically relevant? Am J Respir Med 2003;2(4):287-97
   PubMedGoogle Scholar
• Broadley KJ. Beta-adrenoceptor responses of the airways: for better or worse? Eur J Pharmacol 2006;533(1-3):15-27
   PubMed Web of Science ®Google Scholar
• Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest 2004;125(6):2309-21
   PubMed Web of Science ®Google Scholar
• Fisher AA, Davis MW, McGill DA. Acute myocardial infarction associated with albuterol. Ann Pharmacother 2004;38(12):2045-9
   PubMed Web of Science ®Google Scholar
• Au DH, Curtis JR, Every NR, Association between inhaled beta-agonists and the risk of unstable angina and myocardial infarction. Chest 2002;121(3):846-51
   PubMed Web of Science ®Google Scholar
• Au DH, Lemaitre RN, Curtis JR, The risk of myocardial infarction associated with inhaled beta-adrenoceptor agonists. Am J Respir Crit Care Med 2000;161(3 Pt 1):827-30
   PubMed Web of Science ®Google Scholar
• de Vries F, Pouwels S, Bracke M, Use of beta2 agonists and risk of acute myocardial infarction in patients with hypertension. Br J Clin Pharmacol 2008;65(4):580-6
   PubMed Web of Science ®Google Scholar
• Au DH, Udris EM, Curtis JR, Association between chronic heart failure and inhaled beta-2-adrenoceptor agonists. Am Heart J 2004;148(5):915-20
   PubMed Web of Science ®Google Scholar
• Au DH, Udris EM, Fan VS, Risk of mortality and heart failure excacerbations associated with inhaled beta-adrenoceptor agonists among patients with known left ventricular systolic dysfunction. Chest 2003;123(6):1964-9
   PubMed Web of Science ®Google Scholar
• Mahoney BA, Smith WA, Lo DS, Emergency interventions for hyperkalemia. Cochrane Database Syst Rev 2005;(2):CD003235
   PubMed Web of Science ®Google Scholar
• Ostovar H, Jones J, Brown M. Best evidence topic report. Nebulized levalbuterol or albuterol for lowering serum potassium. Ember Med J 2005;22:366-7
   PubMed Web of Science ®Google Scholar
• Kim HJ, Han SW. Therapeutic approach to hyperkalemia. Nephron 2002;92(Suppl 1):33-40
   PubMed Web of Science ®Google Scholar
• Greenberg A. Hyperkalemia: treatment options. Semin Nephrol 1998;18:46-57
   PubMed Web of Science ®Google Scholar
• Gauvreau GM, Jordana M, Watson RM, Effect of regular inhaled albuterol on allergen-induced late responses and sputum eosinophils in asthmatic subjects. Am J Respir Crit Care Med 1997;156(6):1738-45
   PubMed Web of Science ®Google Scholar
• Cockroft DW, O'Byrne PM, Swystun VA, Bhagat R. Regular use of inhaled albuterol and the allergen-induced late asthmatic response. J Allergy Clin Immunol 1995;96(1):44-9
   PubMed Web of Science ®Google Scholar
• Cockroft DW, McParland CP, Britto SA, Regular inhaled albuterol and airway responsiveness to allergen. Lancet 1993;342:833-7
   PubMed Web of Science ®Google Scholar
• Ipratroprium package insert. Available from: http://docs.google.com/viewer?a=v&q=cache:7k8tN2k5SqsJ:bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser%3FdocBase%3Drenetnt%26folderPath%3D/Prescribing%2BInformation/PIs/Combivent%2BIA/combivent.pdf+atrovent+inhaler+ package+insert&hl=en&gl= us&sig=AHIEtbQyMmpw1Wdxc XaNYqEGAT_xhk0N3w. [Accessed on 16 January 2009]
   Google Scholar
• Anthonisen NR, Connett JE, Enright PL, Hospitalizations and mortality in the Lung Health study. Am J Respir Crit Care Med 2002;166:333-9
   PubMed Web of Science ®Google Scholar
• Ogale SS, Lee TA, Au DH, Cardiovascular events associated with ipratropium bromide in COPD. Chest 2009. [Epub ahead of print]
   Google Scholar
• Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008;300:1439-50
   PubMed Web of Science ®Google Scholar
• Lee TA, Pickard AS, Au DH, Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med 2008;149:380-90
   PubMed Web of Science ®Google Scholar
• Macie C, Wooldrage K, Manfreda J, Anthonisen N. Cardiovascular morbidity and the use of inhaled bronchodilators. Int J Chron Obstruct Pulm Dis 2008;3:163-9
   PubMedGoogle Scholar
• Celli B, Decramer M, Leimer I, Cardiovascular safety of tiotropium in patients with COPD. Chest 2010;137:20-30
   PubMed Web of Science ®Google Scholar
• Tashkin D. Tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2009;360:187
   PubMed Web of Science ®Google Scholar
• Rabe KF. Anticholinergic drugs for the treatment of COPD are safe… Are they? Chest 2010;137:1-3
   PubMed Web of Science ®Google Scholar
• Coskun S, Yuksel H, Tikiz H, Danahaliloğlu S. Standard dose of inhaled albuterol significantly increases QT dispersion compared to low dose of albuterol plus ipratropium bromide therapy in moderate to severe acute asthma attacks in children. Pediatr Int 2001;43(6):631-6
   PubMed Web of Science ®Google Scholar
• Sackett DL, Haynes RB. Compliance with therapeutic regimens. Johns Hopkins University Press, Baltimore; 1976
   Google Scholar
• Campbell SC. Clinical aspects of inhaled anticholinergic therapy. Respir Care 2000;45(7):864-7
   PubMedGoogle Scholar
• Celli BR. Update on the management of COPD. Chest 2008;133:1451-62
   PubMed Web of Science ®Google Scholar
• Medical Research Council Working Party. Long-term domicilliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981;1:681-6
   PubMed Web of Science ®Google Scholar
• Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med 1980;93:391-8
   PubMed Web of Science ®Google Scholar
• Orens JB, Estenne M, Arcasoy S, International guidelines for the selection of lung transplant candidates: 2006 update; a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006;25:745-55
   PubMed Web of Science ®Google Scholar
• National Emphysema Treatment Trial Research Group. Patients at high risk of death after lung-volume-reduction surgery. N Engl J Med 2001;345:1075-83
   PubMed Web of Science ®Google Scholar
• National Emphysema Treatment Trial Research Group. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2004;348:2059-73
   Web of Science ®Google Scholar
• Ries AL, Bauldoff GS, Carlin BW, Pulmonary rehabilitation: joint ACCP/AACVPR evidence-based clinical practice guidelines. Chest 2007;131(Suppl 5):4S-42S
   PubMed Web of Science ®Google Scholar
• Donohue JF, Kalberg C, Emmett A, A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPD. Treat Respir Med 2004;3(3):173-81
   PubMedGoogle Scholar
• Make B, Hanania NA, ZuWallack R, The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: an eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study. Clin Ther 2005;27(5):531-42
   PubMed Web of Science ®Google Scholar
• Bleecker ER, Emmett A, Crater G, Lung function and symptom improvement with fluticasone propionate/salmeterol and ipratropium bromide/albuterol in COPD: response by beta-agonist reversibility. Pulm Pharmacol Ther 2008;21(4):682-8
   PubMed Web of Science ®Google Scholar
• Griffin J, Lee S, Caiado M, Comparison of tiotropium bromide and combined ipratropium/salbutamol for the treatment of COPD: a UK General Practice Research Database 12-month follow-up study. Prim Care Respir J 2008;17(2):104-10
   PubMedGoogle Scholar
• Sutherland ER, Brazinsky S, Feldman G, Nebulized formoterol effect on bronchodilation and satisfaction in COPD patients compared to QID ipratropium/albuterol MDI. Curr Med Res Opin 2009;35:653-61
   Web of Science ®Google Scholar
• Balkissoon R, Make B. A double-blind crossover study comparing the safety and efficacy of three weeks of Flu/Sal 250/50 bid plus albuterol 180 ug prn q4 hours to Flu/Sal 250/50 bid plus albuterol/Ipratropium bromide 2 puffs prn q4 hours in patients with chronic obstructive pulmonary disease. COPD 2008;5(4):221-7
   PubMedGoogle Scholar